IM Cannabis Corp.

IMCC

CA44969Q3070

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 10:03:29 31/05/2024 pm IST			5-day change	1st Jan Change
0.79 ^CAD	+3.95%		+1.28%	+71.74%

29/05	IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding	CI
26/05	IM Cannabis Corp. announced that it expects to receive CAD 2.091977 million in funding	CI

IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 15, 2023 at 05:48 pm IST

IM Cannabis Corp. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CAD 13.17 million compared to CAD 13 million a year ago.

Net income was CAD 0.309 million compared to net loss of CAD 9.45 million a year ago. Basic earnings per share from continuing operations was CAD 0.03. Diluted earnings per share from continuing operations was CAD 0.03.

Basic earnings per share was CAD 0.03. Diluted earnings per share was CAD 0.03.

Latest news about IM Cannabis Corp.

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding	29/05	CI
IM Cannabis Corp. announced that it expects to receive CAD 2.091977 million in funding	26/05	CI
Transcript : IM Cannabis Corp., Q1 2024 Earnings Call, May 08, 2024	08/05
IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market	09/04	CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market	04/04	MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024	28/03
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	25/03	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	25/03	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	25/03	MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis	25/03	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	28/02	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	28/02	CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments	26/02	MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule	31/01	MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition	12/01	MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical	02/01	MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months	08/12	MT
IM Cannabis Announces Receipt of Court Action	27/11	MT
Transcript : IM Cannabis Corp., Q3 2023 Earnings Call, Nov 13, 2023	13/11
IM Cannabis Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
IM Cannabis Secures $1.39 Million in Short-Term Debt	13/23/13	MT
IM Cannabis Corp. Announces Executive Changes	10/23/10	CI
IM Cannabis CFO Steps Down	19/23/19	MT

Chart IM Cannabis Corp.

Duration

Period

More charts

Company Profile

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company